According to Zacks, "Ardelyx, Inc.is a clinical-stage biopharmaceutical company".
Several other hedge funds have also bought and sold shares of ARDX. The company was initiated on Friday, December 18 by BTIG Research. Bank of America Corp DE boosted its position in Ardelyx by 52.6% in the first quarter. The company's 50-day moving average is $8.70 and its 200 day moving average is $12.25. Citigroup Inc. reiterated a "buy" rating and issued a $12.00 target price (down from $17.00) on shares of Ardelyx in a research report on Monday, May 15th. Zacks Investment Research raised shares of Ardelyx from a "sell" rating to a "hold" rating in a research report on Thursday, May 11th.
Teachers Advisors LLC increased its position in Ardelyx Inc (NASDAQ:ARDX) by 45.1% during the fourth quarter, Holdings Channel reports.
TRADEMARK VIOLATION NOTICE: This news story was originally published by Stock Observer and is the sole property of of Stock Observer. American International Group Inc. now owns 18,926 shares of the biopharmaceutical company's stock worth $239,000 after buying an additional 5,765 shares in the last quarter. Alliancebernstein L.P. boosted its stake in shares of Ardelyx by 7.9% in the first quarter. Acuta Capital Partners LLC raised its position in Ardelyx by 3.1% in the fourth quarter. Renaissance Technologies LLC now owns 66,300 shares of the biopharmaceutical company's stock worth $941,000 after buying an additional 19,300 shares in the last quarter. Ardelyx Inc has a 1-year low of $4.05 and a 1-year high of $16.30. The stock has "Buy" rating by BTIG Research on Tuesday, September 22. The biopharmaceutical company reported ($0.59) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.65) by $0.06. Cantor Fitzgerald reiterated a "buy" rating and set a $12.00 price target on shares of Ardelyx in a research note on Wednesday, May 31st. If you are accessing this article on another website, it was illegally copied and reposted in violation of USA and worldwide trademark & copyright legislation. American International Group Inc. boosted its stake in shares of Ardelyx by 43.8% in the first quarter. On average, analysts forecast that Ardelyx, Inc. will post ($2.46) earnings per share for the current fiscal year. The average 12 month target price among brokerages that have issued a report on the stock in the a year ago is $14.13. RA Capital Management LLC now owns 3,266,045 shares of the biopharmaceutical company's stock valued at $42,263,000 after buying an additional 953,802 shares in the last quarter.
Several research firms have recently issued reports on ARDX.
Ardelyx (NASDAQ:ARDX) last released its earnings results on Friday, May 5th. The institutional investor owned 47,230 shares of the biopharmaceutical company's stock after buying an additional 14,690 shares during the period. The stock's market cap is $206.13 million. The original version of this piece can be viewed at https://www.themarketsdaily.com/2017/06/18/ardelyx-inc-ardx-position-raised-by-teachers-advisors-llc-updated.html. One research analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. The Company's products line includes cardiorenal portfolio and gastrointestinal portfolio.